AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical ...
The pandemic stretched us — our communication, our science, our distribution networks, even what it means to be a good ...
As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...
The research field of 'cellular IRESes' lay dormant for decades, as there was no uniform standard of reliable methods for the clear characterization of these starting points for the ribosome-mediated ...
AIM Vaccine Co., Ltd. Class H ( ($HK:6660) ) has provided an update. AIM Vaccine Co., Ltd. has received approval from the U.S. FDA to conduct ...
Shares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) have been assigned an average rating of “Hold” from the twenty-four ...
Moderna (NASDAQ:MRNA – Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $40.00 to ...
Ben McPoland considers a pair of investments that are performing awfully in his ISA portfolio so far this year. What's gone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback